Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

Aberrant NF-κB activity drives oncogenesis and cell survival in multiple myeloma (MM) and many other cancers. However, despite an aggressive effort by the pharmaceutical industry over the past 30 years, no specific IκBα kinase (IKK)β/NF-κB inhibitor has been clinically approved, due to the multiple...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Toxicol Rep
Hoofdauteurs: Tornatore, Laura, Capece, Daria, D'Andrea, Daniel, Begalli, Federica, Verzella, Daniela, Bennett, Jason, Acton, Gary, Campbell, Elizabeth A., Kelly, James, Tarbit, Michael, Adams, Nigel, Bannoo, Selina, Leonardi, Antonio, Sandomenico, Annamaria, Raimondo, Domenico, Ruvo, Menotti, Chambery, Angela, Oblak, Metod, Al-Obaidi, Magda J., Kaczmarski, Richard S., Gabriel, Ian, Oakervee, Heather E., Kaiser, Martin F., Wechalekar, Ashutosh, Benjamin, Reuben, Apperley, Jane F., Auner, Holger W., Franzoso, Guido
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6502747/
https://ncbi.nlm.nih.gov/pubmed/31080744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.toxrep.2019.04.006
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items